Clinical Translation of Spatial Assays Patents: Leaders & Trends 2026
Clinical Translation of Spatial Assays Patents: Who Leads and Where the Gaps Sit
Filing nearly quadrupled from 2021 to 2024, rising from 2 to 8 records a year (+300%), with the most recent years still understated due to publication lag. Annual filings rose from 2 in 2017 to a peak of 8 in 2024, the last year that can be read as complete. The 2021-to-2024 span alone shows +300% growth. 2025 and 2026 figures will continue to rise as publications catch up with filings made in those years, given the roughly 18-month lag between filing and publication.
- 1VENTANA MEDICAL SYSTEMS INC18
- 2ADVANCE SENTRY CORP13
- 3ZYMED LAB7
- 4HACKENSACK MERIDIAN HEALTH INC6
- 5AGENCY FOR SCI TECH & RES5
See the full clinical translation of spatial assays analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about this landscape
Who holds the most patents in clinical translation of spatial assays?
One assignee leads the ranked list with 18 records, well ahead of the rest of the field. The fifth-ranked assignee holds 5 records and the tenth holds 2, showing a steep drop-off after the leader. Altogether the top 5 assignees account for 71.0% of the 69 records in scope, and the top 10 account for 95.7%, so the field is concentrated among a small number of organisations even though 17 companies appear in the ranking overall.
Is patent filing in this area growing or slowing down?
Filing has grown substantially in recent years: annual records rose from 2 in 2021 to a peak of 8 in 2024, a +300% increase over that span. 2025 and 2026 currently show fewer filings, but that reflects the roughly 18-month lag between filing a patent application and its publication, not an actual slowdown. Treat 2024 as the most recent complete year and expect later years to fill in as more publications surface.
What technology areas dominate the patent claims here?
Measurement and testing methods dominate: C12Q (enzyme and DNA measurement) appears in 56.5% of the 69 records and G01N (material analysis and testing) in 52.2%, making them the two largest classes by a clear margin. Lab apparatus (B01L, 30.4%) and genetic engineering (C12N, 29.0%) form a second tier. Because records can carry multiple IPC codes, these percentages overlap and add to more than 100%, but the ranking itself is a reliable guide to where claim density sits.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Clinical Translation of Spatial Assays covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.